fda approval ghk cu drug status ghk-cu ghk-cu peptide fda approval status GHK-CU Peptide GHK-Cu FDA Status and Compounding
Description
This effect is dose-dependent and typically transient, resolving as patients acclimate to therapy

Cortez, E., Roswall, P

10.1016/s0306-4522(01)00210-x 30 BreivogelC

But for some users, nausea becomes dose-limiting
